GLPG Galapagos NV

PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS

PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS
EN
12/10/2020

Underlying

GLPGGalapagos NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV

Galapagos Signs agreement with Gilead on T-cell Engager in autoimmune ...

Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead have now entered into a binding agreement to collaborate on advancing gamgertamig (BCMAxCD3 T cell engager) in autoimmune diseases. This agreement comes after the companies announced their advanced discussions on the collaboration last week. Economically, Galapagos is effectively co-fina...

03/31/26 March 31, 2026 1 EN
Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Lewi
UCB UCB S.A.
AGFB AGFA-GEVAERT NV
GLPG GALAPAGOS NV
IVA INVENTIVA SA
WDP WAREHOUSES DE PAUW SCA
MAAT MAAT PHARMA SA
ONWD ONWARD MEDICAL NV
03/31/26 March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerkin...

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op  Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class & best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Ad...

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 20...

March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos Announces Nomination of Gino Santini to its Board of Directo...

Galapagos Announces Nomination of Gino Santini to its Board of Directors Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine  Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder...

March 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch